Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Rhea-AI Summary

Atossa Therapeutics (Nasdaq: ATOS) presented preclinical data on (Z)-endoxifen at the 2026 MDA Clinical & Scientific Conference showing improved muscle strength, reduced damage biomarkers, better body composition, and tolerance in mdx5Cv dystrophic mice.

The company said results support continued clinical development for Duchenne muscular dystrophy.

News Market Reaction – ATOS

+5.65%

12 alerts

+5.65% News Effect

+8.0% Peak in 3 hr 25 min

+$2M Valuation Impact

$46M Market Cap

1.1x Rel. Volume

On the day this news was published, ATOS gained 5.65%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.0% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $46M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: March 11, 2026

1 metrics

Conference date March 11, 2026 Presentation of (Z)-endoxifen DMD mouse data at MDA Clinical & Scientific Conference

Market Reality Check

Price: $5.05 Vol: Volume 42,670 is below 20...

low vol

$5.05 Last Close

Volume Volume 42,670 is below 20-day average 108,832 (relative volume 0.39x). low

Technical Trading below 200-day MA at $11.15 versus price $4.78, indicating prior weakness.

Peers on Argus

ATOS was marked "up" in the momentum feed while peer CRBP was -4.22% and "down"....

1 Down

ATOS was marked "up" in the momentum feed while peer CRBP was -4.22% and "down". Other biotech peers showed mixed moves (e.g., ADAG +21.16%, ANRO +11.25%, MGNX -2.34%, SPRO +6.58%), pointing to stock-specific rather than sector-wide drivers.

Previous Clinical trial Reports

5 past events · Latest: Jan 16 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 16	Orphan designation DMD	Positive	-1.9%	FDA granted Orphan Drug Designation for (Z)-endoxifen in Duchenne muscular dystrophy.
Jan 06	Study may proceed	Positive	+7.0%	FDA issued “Study May Proceed” letter for metastatic ER+/HER2- breast cancer trial.
Dec 15	Breast trial updates	Positive	-13.4%	Multiple positive (Z)-endoxifen updates presented at SABCS 2025 across four breast cancer settings.
Oct 06	Trial design change	Neutral	-1.0%	EVANGELINE Phase 2 amended to smaller, non‑registrational design with futility rule.
Dec 11	Phase 2 results	Positive	-3.2%	Phase 2 KARISMA-Endoxifen showed statistically significant reductions in mammographic breast density.

Pattern Detected

Clinical and regulatory updates on (Z)-endoxifen often produced muted or negative next-day moves, even when data appeared favorable.

Recent Company History

Over the last year, Atossa has repeatedly highlighted (Z)-endoxifen through clinical and regulatory milestones. Events include full Phase 2 KARISMA breast density results, a streamlined EVANGELINE Phase 2 design, positive SABCS 2025 efficacy data, an FDA “Study May Proceed” letter for metastatic breast cancer on Jan 6, 2026, and Orphan Drug designation for DMD on Jan 16, 2026. Despite several seemingly positive updates, next-day stock reactions often trended modestly negative, underscoring a cautious market response to clinical news.

Historical Comparison

-2.5% avg move · This clinical-trial update continues frequent (Z)-endoxifen news flow; prior same-tag releases avera...

clinical trial

-2.5%

Average Historical Move clinical trial

This clinical-trial update continues frequent (Z)-endoxifen news flow; prior same-tag releases averaged a -2.5% next-day move, showing generally cautious market reactions.

Clinical-trial news shows a progression from Phase 2 breast cancer efficacy readouts and streamlined EVANGELINE design, through broader SABCS 2025 updates, to regulatory steps like the metastatic “Study May Proceed” letter and Orphan Drug designation for DMD.

Market Pulse Summary

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with ong...

Analysis

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with ongoing efforts to position (Z)-endoxifen beyond oncology, including DMD. Historically, clinical-trial headlines produced mixed stock moves, with same-tag events averaging about -2.5%. Investors assessing sustainability would weigh this new DMD preclinical signal against prior breast cancer data, existing regulatory designations, financing needs, and the company’s pattern of sometimes fading gains after favorable updates.

Key Terms

biomarkers, preclinical, histologic, selective estrogen receptor modulator/degrader (SERM/D), +2 more

6 terms

biomarkers medical

"Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic Mice"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

preclinical medical

"trusted, reproducible standard for Duchenne muscular dystrophy (DMD) preclinical research, was used"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

histologic medical

"Key biochemical and histologic markers of muscle damage were reduced"

Relating to the microscopic structure of tissue, 'histologic' describes observations made by examining thin slices of cells and tissue under a microscope. For investors, histologic findings matter because they help determine how a disease is classified, how well a treatment works at the tissue level, and whether regulators or doctors will accept a therapy—think of it like inspecting the weave of fabric to judge quality and suitability for use.

selective estrogen receptor modulator/degrader (SERM/D) medical

"(Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated"

A selective estrogen receptor modulator/degrader (SERM/D) is a drug that both adjusts how cells respond to estrogen and can remove or disable the receptor proteins that let estrogen act, combining a “dimmer switch” effect with a “take out the battery” action. Investors care because these compounds target diseases driven by estrogen signals—so clinical trial results, approvals, or setbacks can rapidly change a drugmaker’s revenue outlook and stock value, similar to how a new, more efficient tool can disrupt an entire market.

pharmacology medical

"oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen"

Pharmacology is the science of how drugs affect the body and how the body affects drugs — including what a drug does, how much is needed, how long it lasts, and possible side effects. For investors, pharmacology matters because it determines whether a medicine is likely to work safely, how it will be dosed, what risks regulators and doctors will see, and therefore how big its market and approval chances might be — like testing a recipe to see if it will reliably satisfy customers.

forward-looking statements regulatory

"This press release contains certain "forward-looking statements" within the meaning of applicable"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. Not financial advice.

Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic Mice

SEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need, presented an oral clinical trial update on (Z)-endoxifen at the MDA Clinical & Scientific Conference on March 11, 2026, in Orlando, FL.

Presentation Highlights

• The mdx5Cv Dystrophic mouse model, a trusted, reproducible standard for Duchenne muscular dystrophy (DMD) preclinical research, was used for this study
• (Z)-Endoxifen improved muscle strength and motor performance in both juvenile and adult dystrophic mice
• Treatment enhanced resistance to contraction-induced muscle injury
• Favorable changes were observed in body composition, including increased lean mass and reduced fat mass
• Key biochemical and histologic markers of muscle damage were reduced
• The therapy was well tolerated with no adverse findings observed during the study

Clinical Significance
DMD is a progressive and ultimately fatal neuromuscular disorder characterized by ongoing muscle degeneration, inflammation, and fibrosis. While current therapies have improved disease management, a significant unmet medical need for additional therapies remains.

The preclinical findings demonstrate that (Z)-endoxifen may address multiple aspects of DMD pathology, including muscle weakness, structural damage, and functional decline. These results support further clinical investigation of (Z)-endoxifen as a potential new therapeutic option.

"These findings demonstrate the potential of (Z)-endoxifen to meaningfully reduce muscle damage and potentially improve muscle performance in a nonclinical model of Duchenne muscular dystrophy," said Dr. Steven C. Quay, M.D., Ph.D., Chairman and Chief Executive Officer of Atossa Therapeutics. "We believe these data support continued clinical development of (Z)-endoxifen as a potential broad new therapeutic option for patients with DMD."

About Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy is a rare, progressive, neuromuscular disorder caused by one or more mutations in the dystrophin gene. Symptoms typically emerge in early childhood and include progressive muscle weakness, loss of ambulation, respiratory compromise, and cardiomyopathy. DMD is uniformly fatal, often in early adulthood, and despite recent therapeutic advances, there remains a substantial unmet medical need for safe, effective, and accessible treatments.

About (Z)-Endoxifen
(Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company's proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa's (Z)-endoxifen is not approved for any indication.

Atossa's (Z)-endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide.

About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet need. The Company's lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings. Atossa's strategy emphasizes disciplined capital allocation, focusing resources on programs and data packages that can enable future regulatory submissions and potential commercialization. For more information, visit www.atossatherapeutics.com and refer to Atossa's filings with the U.S. Securities and Exchange Commission (SEC).

Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of applicable securities laws, including but not limited to, our expectations regarding the Company's development and regulatory strategy and related milestones, the potential indications that the Company may pursue for (Z)-Endoxifen, the potential for (Z)-Endoxifen to receive regulatory approval and the timing thereof, expectations regarding the design, enrollment, data, timing, results and outcomes of the Company's clinical studies, and the potential market and growth opportunities for the Company. Words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "design," "predict," "future," or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: our ability to successfully execute our strategy to shorten our clinical development timelines for oncology indications, DMD indication, or other indications for our lead program, (Z)-Endoxifen; expected timing, completion and results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa's filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-presents-clinical-trial-update-highlighting-z-endoxifen-research-at-the-2026-mda-clinical--scientific-conference-302706354.html

SOURCE Atossa Therapeutics Inc

FAQ

What did Atossa announce about (Z)-endoxifen in Duchenne muscular dystrophy on March 11, 2026 (ATOS)?

Atossa reported that (Z)-endoxifen improved muscle strength and motor performance in mdx5Cv dystrophic mice. According to the company, the study showed reduced biochemical and histologic markers of muscle damage and favorable body composition changes, supporting further clinical investigation.

Did Atossa report safety findings for (Z)-endoxifen at the 2026 MDA conference (ATOS)?

Yes. The study found (Z)-endoxifen was well tolerated with no adverse findings observed in the mouse study. According to the company, tolerability and pharmacology appear distinct from tamoxifen in their proprietary oral formulation.

What preclinical model did Atossa use for (Z)-endoxifen Duchenne research (ATOS)?

Atossa used the mdx5Cv dystrophic mouse model, a standard preclinical model for Duchenne muscular dystrophy. According to the company, this model demonstrated improved resistance to contraction-induced muscle injury and functional benefits after treatment.

Does the March 12, 2026 update state (Z)-endoxifen is approved for DMD (ATOS)?

No. (Z)-endoxifen is not approved for any indication. According to the company, the results are preclinical and intended to support further clinical development and regulatory evaluation, not current approval status.

How do Atossa’s (Z)-endoxifen findings affect future clinical plans for DMD (ATOS)?

The findings support continued clinical development of (Z)-endoxifen as a potential DMD therapy. According to the company, positive preclinical effects on muscle performance and damage markers justify further clinical investigation.

What mechanisms or properties of (Z)-endoxifen did Atossa highlight in the March 2026 update (ATOS)?

(Z)-endoxifen is described as a SERM/D with ER-targeted effects and PKC inhibition distinct from tamoxifen. According to the company, its proprietary oral formulation shows favorable safety and pharmacology across oncology and rare disease programs.